{"id":"immediate-release-tacrolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache, paresthesia)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase critical for dephosphorylating NFAT (nuclear factor of activated T cells). By preventing NFAT translocation to the nucleus, tacrolimus blocks the transcription of IL-2 and other cytokines essential for T-cell proliferation and differentiation. The immediate-release formulation provides faster absorption compared to extended-release formulations.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:09.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune conditions (off-label use in various settings)"}]},"trialDetails":[{"nctId":"NCT06751992","phase":"PHASE4","title":"Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-17","conditions":"Kidney Transplant Recipients, Old Age","enrollment":92},{"nctId":"NCT07290777","phase":"PHASE2","title":"VEL-101 to Prevent Rejection After Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Veloxis Pharmaceuticals","startDate":"2026-07","conditions":"Transplantation, Kidney","enrollment":120},{"nctId":"NCT03979365","phase":"PHASE4","title":"Envarsus XR Compared to Immediate Release Tacrolimus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-07-18","conditions":"Kidney Transplant Recipients","enrollment":261},{"nctId":"NCT02882828","phase":"PHASE4","title":"PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2016-10","conditions":"Allograft","enrollment":134},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT03769298","phase":"PHASE2, PHASE3","title":"CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2019-02-27","conditions":"Kidney Pancreas Transplantation","enrollment":20},{"nctId":"NCT03689075","phase":"PHASE4","title":"Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation","status":"TERMINATED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2018-11-01","conditions":"Kidney Transplant Failure, Allosensitization, Immunosuppression","enrollment":35},{"nctId":"NCT03461445","phase":"PHASE4","title":"Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2018-04-01","conditions":"Kidney Transplant; Complications, Toxicity, Drug Toxicity","enrollment":64},{"nctId":"NCT04646356","phase":"PHASE2","title":"Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-10-20","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed","enrollment":10},{"nctId":"NCT03823768","phase":"PHASE4","title":"Envarsus Neurotoxicity Burden in Liver Transplant Patients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2020-01-31","conditions":"Neurotoxicity, Liver Transplant; Complications","enrollment":30},{"nctId":"NCT02723591","phase":"PHASE4","title":"To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-09-09","conditions":"Kidney Transplantation","enrollment":599},{"nctId":"NCT06183892","phase":"NA","title":"Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-04","conditions":"Liver Transplant","enrollment":80},{"nctId":"NCT04489134","phase":"PHASE2","title":"P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2022-02-15","conditions":"Pharmacokinetics","enrollment":27},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT03644485","phase":"PHASE4","title":"Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-10-21","conditions":"Kidney Transplant","enrollment":284},{"nctId":"NCT03410654","phase":"EARLY_PHASE1","title":"Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-10-24","conditions":"Kidney Transplant; Complications","enrollment":28},{"nctId":"NCT04711291","phase":"NA","title":"Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Medication Adherence, Renal Transplant","enrollment":""},{"nctId":"NCT03511560","phase":"PHASE4","title":"Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-07-26","conditions":"Renal Transplant Rejection, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT04225988","phase":"PHASE4","title":"Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-01-09","conditions":"Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03760263","phase":"PHASE4","title":"Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus","status":"COMPLETED","sponsor":"Sentara Norfolk General Hospital","startDate":"2020-01-16","conditions":"Transplant;Failure,Kidney","enrollment":46},{"nctId":"NCT04420195","phase":"PHASE2","title":"Envarsus XR in Lung Transplant","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-10-23","conditions":"Lung Transplant","enrollment":41},{"nctId":"NCT05089604","phase":"PHASE4","title":"Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-01-09","conditions":"Liver Transplantation, Immunosuppression, Neurotoxicity","enrollment":124},{"nctId":"NCT06147648","phase":"PHASE4","title":"Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-12-01","conditions":"Liver Transplantation","enrollment":352},{"nctId":"NCT03864926","phase":"PHASE4","title":"Envarsus in Delayed Graft Function (E-DGF)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-03-18","conditions":"Delayed Graft Function","enrollment":100},{"nctId":"NCT05001074","phase":"PHASE3","title":"Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients","status":"UNKNOWN","sponsor":"Heleen Grootjans","startDate":"2020-07-28","conditions":"Lung Transplant; Complications","enrollment":145},{"nctId":"NCT03266393","phase":"PHASE4","title":"Envarsus XR® in Adolescent Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2019-01-15","conditions":"Kidney Transplantation, Renal Transplantation, Grafting, Kidney","enrollment":28},{"nctId":"NCT04917718","phase":"PHASE4","title":"Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus","status":"UNKNOWN","sponsor":"Loyola University","startDate":"2021-08-16","conditions":"Chronic Kidney Diseases, Heart Transplant","enrollment":42},{"nctId":"NCT03703154","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-10-25","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT03437577","phase":"PHASE1, PHASE2","title":"Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2018-05-08","conditions":"Kidney Transplant Failure and Rejection","enrollment":18},{"nctId":"NCT04526431","phase":"","title":"Tacrolimus Pharmacokinetic Subpopulations","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2020-07-28","conditions":"Kidney Transplant Failure and Rejection, Immunosuppression-related Infectious Disease","enrollment":180},{"nctId":"NCT03465410","phase":"PHASE4","title":"OPTImization of the Dose of tacroliMUS by Bayesian Prediction","status":"COMPLETED","sponsor":"NURIA LLOBERAS BLANCH","startDate":"2017-03-21","conditions":"KIDNEY TRANSPLANTATION","enrollment":96},{"nctId":"NCT03263052","phase":"","title":"Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2017-07-01","conditions":"Disorder Related to Renal Transplantation","enrollment":40},{"nctId":"NCT01681134","phase":"PHASE1","title":"A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Canada, Inc.","startDate":"2012-07","conditions":"Healthy","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf"],"phase":"marketed","status":"active","brandName":"immediate-release tacrolimus","genericName":"immediate-release tacrolimus","companyName":"University of Minnesota","companyId":"university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation to suppress immune responses. Used for Organ transplant rejection prophylaxis (kidney, heart, liver), Atopic dermatitis, Autoimmune conditions (off-label use in various settings).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}